Charlie Johnson brings over 20 years experience in strategic development, commercialization and management of service businesses within the oncology sector. With a notable track record in the ADC segment going back to 2004 when he established Avecia’s ADC manufacturing operations when the segment was in its infancy. Prior to joining ADC Biotechnology as Chief Executive in early 2012, Johnson held positions as Director for the High Potency Division of Dishman group’s Carbogen Amcis operation, headquartered in Basel and as Business Manager for the strategic marketing of the oncology portfolio of Italy’s UQUIFA. He previously held a series of pharma-related roles with ICI and AstraZeneca.
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policy makers.